850 related articles for article (PubMed ID: 20949583)
21. Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction.
Toso A; Leoncini M; Maioli M; Gallopin M; Tedeschi D; Amato M; Bellandi F
J Cardiovasc Med (Hagerstown); 2011 May; 12(5):318-21. PubMed ID: 21045713
[TBL] [Abstract][Full Text] [Related]
22. Is atrial fibrillation a risk factor for contrast-induced nephropathy in patients with ST-elevation myocardial infarction?
Ballı M; Taşolar H; Çetin M; Hatem E; Çağlıyan ÇE; Şeker T; Çaylı M
J Cardiol; 2016 Apr; 67(4):327-30. PubMed ID: 26589269
[TBL] [Abstract][Full Text] [Related]
23. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention.
Jabara R; Gadesam RR; Pendyala LK; Knopf WD; Chronos N; Chen JP; Viel K; King SB; Manoukian SV
Am J Cardiol; 2009 Jun; 103(12):1657-62. PubMed ID: 19539072
[TBL] [Abstract][Full Text] [Related]
24. Insulin Resistance Increases the Risk of Contrast-Induced Nephropathy in Patients Undergoing Elective Coronary Intervention.
Li Y; Liu Y; Shi D; Yang L; Liang J; Zhou Y
Angiology; 2016 Feb; 67(2):139-45. PubMed ID: 25843952
[TBL] [Abstract][Full Text] [Related]
25. Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.
Fan Y; Wei Q; Cai J; Shi Y; Zhang Y; Yao L; Wang X; Lin S; Li Y; Lv J; Zhou B; Du R
Heart Vessels; 2016 Nov; 31(11):1776-1782. PubMed ID: 26874946
[TBL] [Abstract][Full Text] [Related]
26. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality.
Marenzi G; Assanelli E; Campodonico J; Lauri G; Marana I; De Metrio M; Moltrasio M; Grazi M; Rubino M; Veglia F; Fabbiocchi F; Bartorelli AL
Ann Intern Med; 2009 Feb; 150(3):170-7. PubMed ID: 19189906
[TBL] [Abstract][Full Text] [Related]
27. Red cell distribution width predicts contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
Kurtul A; Yarlioglues M; Murat SN; Demircelik MB; Acikgoz SK; Ergun G; Duran M; Cetin M; Ornek E
Angiology; 2015 May; 66(5):433-40. PubMed ID: 24834929
[TBL] [Abstract][Full Text] [Related]
28. Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for ST-elevation myocardial infarction.
Rasoul S; Ottervanger JP; de Boer MJ; Dambrink JH; Hoorntje JC; Marcel Gosselink AT; Zijlstra F; Suryapranata H; van 't Hof AW;
Coron Artery Dis; 2009 Sep; 20(6):415-21. PubMed ID: 19641460
[TBL] [Abstract][Full Text] [Related]
29. Association Between Acidosis Soon After Reperfusion and Contrast-Induced Nephropathy in Patients With a First-Time ST-Segment Elevation Myocardial Infarction.
Gohbara M; Hayakawa A; Akazawa Y; Furihata S; Kondo A; Fukushima Y; Tomari S; Endo T; Kimura K; Tamura K
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28835362
[TBL] [Abstract][Full Text] [Related]
30. Risk scoring system for prediction of contrast-induced nephropathy in patients with pre-existing renal impairment undergoing percutaneous coronary intervention.
Chong E; Shen L; Poh KK; Tan HC
Singapore Med J; 2012 Mar; 53(3):164-9. PubMed ID: 22434288
[TBL] [Abstract][Full Text] [Related]
31. [Clinical impact of nephropathy induced by contrast medium in patients with acute myocardial infarction undergoing emergent coronary angiography].
Jujo K; Yamaguchi J; Obayashi K; Suzuki K; Sekiguchi H; Nagashima M; Tsurumi Y; Kasanuki H
J Cardiol; 2006 Jul; 48(1):9-16. PubMed ID: 16886495
[TBL] [Abstract][Full Text] [Related]
32. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
Saltzman AJ; Stone GW; Claessen BE; Narula A; Leon-Reyes S; Weisz G; Brodie B; Witzenbichler B; Guagliumi G; Kornowski R; Dudek D; Metzger DC; Lansky AJ; Nikolsky E; Dangas GD; Mehran R
JACC Cardiovasc Interv; 2011 Sep; 4(9):1011-9. PubMed ID: 21939942
[TBL] [Abstract][Full Text] [Related]
33. A simple risk score model for predicting contrast-induced nephropathy after coronary angiography in patients with diabetes.
Zeng JF; Chen SQ; Ye JF; Chen Y; Lei L; Liu XQ; Liu Y; Wang Y; Lin JJ; Chen JY
Clin Exp Nephrol; 2019 Jul; 23(7):969-981. PubMed ID: 31049747
[TBL] [Abstract][Full Text] [Related]
34. B-type natriuretic peptide and risk of contrast-induced acute kidney injury in acute ST-segment-elevation myocardial infarction: a substudy from the HORIZONS-AMI trial.
Jarai R; Dangas G; Huber K; Xu K; Brodie BR; Witzenbichler B; Metzger DC; Radke PW; Yu J; Claessen BE; Genereux P; Mehran R; Stone GW
Circ Cardiovasc Interv; 2012 Dec; 5(6):813-20. PubMed ID: 23192919
[TBL] [Abstract][Full Text] [Related]
35. Elevated homocysteine and the risk of contrast-induced nephropathy: a cohort study.
Barbieri L; Verdoia M; Schaffer A; Niccoli G; Perrone-Filardi P; Bellomo G; Marino P; Suryapranata H; Luca GD
Angiology; 2015 Apr; 66(4):333-8. PubMed ID: 24830422
[TBL] [Abstract][Full Text] [Related]
36. Impact of Chronic Statin Therapy on Postprocedural Contrast-Induced Nephropathy in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention.
Chanin JM; Yang DC; Haider MA; Swaminathan RV; Kim LK; Charitakis K; Tanoue M; Minutello RM; Gade CL; Singh HS; Bergman G; Wong SC; Feldman DN
J Invasive Cardiol; 2015 Nov; 27(11):490-6. PubMed ID: 25999136
[TBL] [Abstract][Full Text] [Related]
37. The impact of iso-osmolar contrast use in emergent percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Kanei Y; Ayabe K; Ratcliffe J; Vales L; Nakra N; Friedman P; Fox J
J Invasive Cardiol; 2011 Nov; 23(11):448-50. PubMed ID: 22045075
[TBL] [Abstract][Full Text] [Related]
38. Relation of homocysteinemia to contrast-induced nephropathy in patients undergoing percutaneous coronary intervention.
Kim SJ; Choi D; Ko YG; Kim JS; Han SH; Kim BK; Kang SW; Hong MK; Jang Y; Choi KH; Yoo TH
Am J Cardiol; 2011 Oct; 108(8):1086-91. PubMed ID: 21791335
[TBL] [Abstract][Full Text] [Related]
39. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Different Risk Scores for Predicting Contrast Induced Nephropathy and Outcomes After Primary Percutaneous Coronary Intervention in Patients With ST Elevation Myocardial Infarction.
Liu YH; Liu Y; Zhou YL; He PC; Yu DQ; Li LW; Xie NJ; Guo W; Tan N; Chen JY
Am J Cardiol; 2016 Jun; 117(12):1896-903. PubMed ID: 27161818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
